Expanding support for adolescents with opioid use disorder
Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD
This study is testing a new way to support teenagers with opioid use disorder by involving their families and making it easier for them to stick to their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 13 Years to 21 Years |
| Sex | All |
| Sponsor | Potomac Health Foundations Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06774248 on ClinicalTrials.gov |
What this trial studies
This project aims to enhance the Youth Opioid Recovery Support (YORS) intervention for adolescents struggling with opioid use disorder (OUD). The intervention focuses on increasing adherence to medications for opioid use disorder (MOUD) through family involvement, assertive outreach, and low-barrier access to treatment. By adapting the YORS intervention, which has shown efficacy in young adults, this study seeks to address the unique needs of adolescents, particularly those using sublingual buprenorphine. The goal is to improve treatment outcomes and reduce opioid relapse among this underserved population.
Who should consider this trial
Good fit: Ideal candidates for this study are adolescents aged 13-17 who have a documented diagnosis of opioid use disorder and are willing to involve a family member in their treatment.
Not a fit: Patients who are not English-speaking or those who do not have a legal guardian willing to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve treatment adherence and reduce relapse rates in adolescents with opioid use disorder.
How similar studies have performed: Previous studies have shown success with similar interventions in young adults, indicating potential for effectiveness in adolescents as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for adolescent patients with OUD: 1. English speaking 2. Provision of signed and dated informed assent form (may be collected verbally over audio and/or video platform in the event of a remote enrollment) 3. Willing to have a legal, English-speaking guardian provide informed consent (may be collected verbally over audio and/or video platform in the event of a remote enrollment) 4. Stated willingness to comply with all study procedures and the YORS intervention 5. Age 13-21 (inclusive) 6. Documented diagnosis of opioid use disorder (OUD) 7. Presenting for an index episode of inpatient or outpatient treatment at Maryland Treatment Centers with at least one day of opioid use in the 30 days prior to enrollment 8. Considering treatment with XR-NTX, XR-BUP, or SL-BUP\* OR has begun SL-BUP maintenance treatment within the past two weeks 9. Willing to designate a parent, family member, or other person to be involved in their OUD treatment as a Treatment Significant Other 10. Access to a mobile phone Inclusion criteria for Treatment Significant Other (TS) participants 1. English speaking 2. Provision of signed and dated informed consent form (may be collected verbally over audio and/or video platform in the event of a remote enrollment) 3. Stated willingness to comply with all study procedures and the YORS intervention 4. Parent, legal guardian, or other treatment support person designated by an adolescent patient participant to be involved in their OUD treatment as a Treatment Significant Other 5. Age 18 years or older 6. Access to a mobile phone Exclusion Criteria for adolescent patients with OUD: 1. Psychiatric or medical instability that, in the opinion of the PI, would preclude participation in the trial (e.g., suicidality, psychosis, Sickle Cell disease with frequent crises) 2. Living situation that, in the opinion of the PI, would preclude participation in the trial (e.g., location greater than 75 miles from the treatment center, homelessness) Exclusion Criteria for Treatment Significant Other (TSO) Participants: 1\. Known to currently be sharing drugs with the adolescent participant
Where this trial is running
Baltimore, Maryland
- Maryland Treatment Centers — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Study coordinator: Kevin Wenzel, PhD
- Email: kwenzel@marylandtreatment.org
- Phone: 410-233-1400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.